Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no... However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
- Mechanism
- Curator reviewed
Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced.
- Primary indication
- Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction.Curator reviewed
- Formula / weight
- C18H17F3N2O3 · 366.3344 g/mol (avg)
- Code names
- R-68070
Resolves to
GLLPUTYLZIKEGF-HAVVHWLPSA-NSMILESOC(=O)CCCCO\N=C(\C1=CN=CC=C1)C1=CC(=CC=C1)C(F)(F)FWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Ridogrel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account